Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPAR-SLE
NCT02338999Phase 2Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jun 2015
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pioglitazone in systemic lupus erythematosus (SLE) (2 arms), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Primary endpoints: Cardio-ankle vascular index at 8 months, Pulse wave velocity at 8 months and 2 more. Started Jun 2015; status: completed.
02
Drugs
pioglitazone
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02338999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338999.